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HER2 (ErbB2, Neu) is a member of the
epidermal growth factor receptor family
and is activated either by homodimeriza-
tion that occurs upon overexpression or
by growth factors following formation of
heterodimers with other members of the
ErbB family. HER2 is overexpressed in a
large number of cancers, including ~30%
of breast cancers, and is an important
target in breast cancer therapy where
treatment with the anti-HER2 monoclonal
antibody trastuzumab (Herceptin) has
proven effective (Slamon et al., 2001).
HER2 overexpression appears to play an
important role in promoting metastasis,
although the mechanism for this is poorly
understood. Li et al. (2004) provide new
insight into the mechanism of HER2-
mediated metastasis by identifying a link
between HER2 and CXCR4, a G protein-
coupled receptor (GPCR) previously
implicated in breast cancer metastasis
(Muller et al., 2001).
Li et al. (2004) demonstrate that
overexpression of HER2 in breast can-
cer cells increases expression of
CXCR4, while inhibition of HER2 expres-
sion using trastuzumab or RNAi treat-
ment results in a corresponding
reduction in CXCR4 expression. A pri-
mary mechanism for the HER2-promot-
ed increase in CXCR4 expression
appears to involve the ability of HER2 to
increase the translation of CXCR4 via
activation of a phosphatidylinositol 3-
kinase/Akt/mTOR signaling pathway
(Figure 1). Previous studies have also
demonstrated that HER2 can activate
the NF-κB pathway (Zhou et al., 2000)
and that NF-κB activation enhances
CXCR4 expression (Helbig et al., 2003),
although these two processes have not
been linked in breast cancer cells.
Moreover, recent studies suggest that
von Hippel-Lindau tumor suppressor
pVHL negatively regulates CXCR4
expression, a process that is dysregulat-
ed under hypoxic conditions (Staller et
al., 2003). Thus, multiple mechanisms
appear to coordinately regulate the
expression of CXCR4.
Interestingly, HER2 also appears to
regulate the rate of CXCR4 degradation in
breast cancer cells (Li et al., 2004).
Previous studies have demonstrated that
CXCR4 degradation involves ligand-
dependent ubiquitination of the receptor
by the E3 ubiquitin ligase AIP4 (Marchese
et al., 2003). CXCR4 activation by the lig-
and CXCL12 (also called stromal cell-
derived factor or SDF-1) regulates receptor
endocytosis, while CXCR4 ubiquitination
promotes the subsequent sorting of the
endocytosed receptor to the lysosome
where it is degraded. Interestingly, HER2
appears to inhibit CXCR4 degradation by
inhibiting CXCL12-promoted ubiquitina-
tion of the receptor (Li et al., 2004).
Although the mechanism of this inhibition
is unclear, the requirement for HER2 tyro-
sine kinase activity suggests that HER2-
promoted signaling may regulate the
mechanisms involved in targeting CXCR4
for ubiquitination. While the detailed
mechanism of CXCL12-promoted ubiqui-
tination of CXCR4 has not been elucidat-
ed, it likely involves phosphorylation of the
receptor by a G protein-coupled receptor
kinase (GRK), binding of an arrestin, and
subsequent targeting of the receptor for
ubiquitination by AIP4. It is possible that
the initial steps in this process are disrupt-
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Unlocking the mysteries of cell metastasis, a major cause of cancer mortality, is essential in the development of novel ther-
apies. In this issue of Cancer Cell, Li et al. (2004) identify a link between HER2 and CXCR4, two receptors previously impli-
cated in breast cancer progression and metastasis. HER2 enhances the expression of CXCR4 by stimulating CXCR4
translation and attenuating CXCR4 degradation. Importantly, coexpression of HER2 and CXCR4 occurs in ~22% of human
breast tumors and correlates with poor survival of breast cancer patients.
Figure 1. Role of HER2 and CXCR4 in cell migration, adhesion, and invasion
CXCL12 (SDF-1α)-promoted chemotaxis through CXCR4 involves activation of the het-
erotrimeric G protein αi and may involve arrestins and activation of p38 MAP kinase (Sun et al.,
2002). Activated CXCR4 also appears to enhance integrin-mediated adhesion, which may
require RhoA, Cdc42, and actin (Soede et al., 2001). Taken together, these processes con-
tribute to CXCR4-mediated migration, adhesion, and invasion. In order to ensure that signals
are of the appropriate magnitude and duration, CXCR4 is also subject to a complex series of
regulatory events. Upon ligand binding, CXCR4 is rapidly monoubiquitinated by the E3 ubiquitin
ligase AIP4 (Marchese et al., 2003). The ubiquitin moiety (Ub) serves as a sorting signal to enter
the multivesicular body (MVB) for subsequent degradation in lysosomes. Overexpression of
HER2 leads to increased expression of CXCR4, which appears to occur via two independent
mechanisms (Li et al., 2004). One is through a PI3K/Akt/mTOR-mediated pathway that leads to
an increase in the rate of CXCR4 synthesis. HER2 overexpression also attenuates CXCR4 ubiqui-
tination and degradation of the receptor, potentially enhancing recycling of CXCR4 to the cell
surface. The increased surface expression of CXCR4 makes the cells more responsive to
CXCL12 stimulation and can result in increased metastasis.
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ed by HER2 overexpression, although
GRK6 and arrestin-3 appear to play stim-
ulatory roles in CXCL12-promoted migra-
tion of lymphocytes (Fong et al., 2002).
The ubiquitination machinery is another
potential target for inhibition by HER2
overexpression, although little is presently
known about whether AIP4 activity is reg-
ulated. Interestingly, overexpression of
AIP4 completely inhibits the ability of
HER2 to enhance CXCR4 expression (Li
et al., 2004). This may reflect an
enhanced rate of CXCR4 degradation but
also suggests that AIP4 might play an
inhibitory role in the enhanced translation
of CXCR4, perhaps by promoting ubiquiti-
nation of components in the mTOR or NF-
κB pathways.
The defect in CXCR4 degradation in
breast cancer cells overexpressing HER2
is also interesting in light of a recent study
demonstrating that ligand-promoted
degradation of the protease-activated
receptor 1 (PAR1) is also defective in sev-
eral breast cancer cell lines (Booden et
al., 2004). Previous studies have implicat-
ed a role for increased expression of
PAR1, a GPCR for the enzyme thrombin,
in breast cancer cell invasion. Although
the detailed mechanism of PAR1 degra-
dation is unknown, it is intriguing that
attenuation of the normal regulatory
mechanisms that attenuate CXCR4 and
PAR1 function appear to be dysfunctional
in breast cancer cells.
The role of HER2 and CXCR4 in cell
invasion was also investigated by Li et al.
(2004). Interestingly, the HER2-promot-
ed increase in CXCR4 expression was
essential for CXCL12-promoted cell
invasion, migration, and adhesion.
Importantly, CXCL12-promoted invasion
of BT474 cells (that have high endoge-
nous levels of HER2) was effectively
inhibited by treatment with either CXCR4
inhibitory antibodies or with trastuzumab,
thus providing a clear link between HER2
and CXCR4 in breast cancer cell inva-
sion. Indeed, previous studies have impli-
cated a role for CXCR4 in breast cancer
metastasis (Muller et al., 2001) as well as
metastasis of colon and prostate cancer
(Kucia et al., 2004). To further establish a
link between HER2 and CXCR4 in breast
cancer, Li et al. (2004) also developed a
retroviral RNAi to inhibit CXCR4 expres-
sion. This retrovirus effectively inhibited
CXCR4 expression and attenuated basal
and CXCL12-promoted invasion of
HER2-expressing cells. A breast cancer
mouse model was also used to evaluate
the effect of reduced CXCR4 expression
on breast cancer cell metastasis to the
lung. These studies clearly demonstrate
the important role of CXCR4 overexpres-
sion in breast cancer cell metastasis, a
finding previously observed by Muller et
al. (2001). A link between HER2 and
CXCR4 expression was also observed in
human breast tumors with ~22% of the
tumors found to coexpress high levels of
HER2 and CXCR4. Importantly, high
expression of CXCR4 also correlated with
a poor overall survival rate.
The study by Li et al. (2004) identifies
a clear link between HER2 and CXCR4
and demonstrates that CXCR4 overex-
pression plays a central role in HER2-
mediated metastasis. So how does
CXCR4 regulate metastasis? The prevail-
ing theory is that the ability of chemokine
receptors to mediate cancer metastasis is
similar to their normal function in regulat-
ing cell migration (Moore, 2001). CXCR4
controls the migration of multiple cell
types, including hematopoietic stem cells,
germ cells, lymphocytes, and neurons, to
sites that express CXCL12. The high lev-
els of CXCL12 in the bone marrow, lung,
liver, and regional lymph nodes provides a
likely mechanism as to why these tissues
are the primary sites for metastasis of
cancers that have been linked to CXCR4
overexpression such as breast, colon,
and prostate. CXCL12 binding to CXCR4
activates multiple pathways that function
to regulate cell invasion and migration.
These include increased expression of
adhesion molecules such as VLA4 and
LFA-1 as well as the matrix metallopro-
teinase MMP9, thus enhancing the ability
of these cells to cross endothelium and
basement membrane (Moore, 2001).
Multiple signaling pathways that function
to promote cell migration are also activat-
ed by CXCR4, including stimulation of
actin polymerization and pseudopodia
formation. The central role of CXCR4 in
cancer metastasis also raises the ques-
tion as to whether CXCR4 can serve as
an important diagnostic and/or target in
the detection and treatment of cancer.
Given the importance of CXCR4 in devel-
opment and normal immune function, it is
likely that complete inhibition of CXCR4
activity would be detrimental. However,
the ability of CXCR4 to promote cancer
cell metastasis appears to be linked to its
overexpression in cancer cells. Thus,
CXCR4 overexpression in cells that nor-
mally have low levels of this receptor
might prove to be a useful diagnostic to
identify cells that have the potential to
metastasize. It is also important to further
establish the mechanisms that result in
increased CXCR4 expression and poten-
tially target such pathways in cancer treat-
ment. Thus, understanding the
mechanisms that normally regulate
CXCR4 expression and function should
prove useful in the treatment and preven-
tion of cancer metastasis.
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